Lucid Ms
Lucid-MS is a patented neuroprotective compound designed to prevent and reverse myelin degradation in multiple sclerosis. First-in-human dosing complete.

Quantum BioPharma is a biopharmaceutical company building a portfolio of assets for the treatment of neurodegenerative and metabolic disorders.
quantumbiopharma.comCrawled Nov 15, 2026
Lucid-MS is a patented neuroprotective compound designed to prevent and reverse myelin degradation in multiple sclerosis. First-in-human dosing complete.
The page offers insights on Multiple Sclerosis (MS) and its effects on the central nervous system, along with therapies for neuro disorders.
UNBUZZD is a science-backed functional beverage designed to support alcohol metabolism and restore mental alertness after drinking. Available online now.
Quantum BioPharma is suing for over $700 million in damages related to alleged stock manipulation.
Quantum BioPharma shares updates on its therapies for neuro disorders and related market news.
The page provides access to Quantum BioPharma’s press releases and financial updates on its therapies for neuro disorders.
The page introduces Quantum BioPharma’s leadership, including its management, board of directors, regulatory advisors, and research team specializing in multiple sclerosis.
Quantum BioPharma’s 2022 Board Diversity Matrix outlines gender identity and representation on its board.
Quantum BioPharma’s Australian subsidiaries focus on developing therapies for neurological disorders, including clinical trials.
Quantum BioPharma emphasizes ethical practices and transparency, providing access to its Code of Conduct and investor resources.
Quantum BioPharma develops therapies for neurological disorders.
Quantum BioPharma develops therapies for brain and inflammatory disorders.
Quantum BioPharma outlines policies for protecting personal information and employee data responsibilities.
Quantum BioPharma’s Whistleblower Policy allows confidential reporting of stock manipulation with potential rewards up to $7 million.
Law firm **Grant & Eisenhofer** files a class action lawsuit against **CIBC and RBC**, accusing the banks of manipulating **Quantum BioPharma’s stock** through illegal market activities. The suit, filed on behalf of shareholder **Paul Durkacz**, alleges that investors who sold securities between **January 2021 and October 2025** suffered significant losses. Quantum BioPharma, formerly **FSD Pharma Inc.**, is named as the affected company in the legal action.
Quantum Biopharma reports significant financial improvements in 2024, including stronger cash reserves, working capital, and operating efficiency. The company also resolves material uncertainty over its going-concern status. Progress in its pipeline includes the completion of the unbuzzd™ clinical trial and Phase 1 results for the multiple sclerosis drug candidate, Lucid-21-302.
Quantum Biopharma appears in court on January 24, 2025, to seek a declaration that Dr. Raza Bokhari is a vexatious litigant. The company has previously won litigation awards totaling approximately **$3 million** in its favor.
Quantum Biopharma Ltd. begins trading on Upstream’s global securities platform under the ticker symbol **QNTM**. The company now lists its shares on the app, expanding accessibility for investors.
Quantum Biopharma closes a second funding tranche, issuing 500 debenture units for **$500,000** under its December 5, 2024 offering. The company, listed on NASDAQ, CSE, and Frankfurt exchanges, expands its capital raise following the initial announcement. The funds support ongoing operations in biopharmaceutical development.
Quantum Biopharma acquires **$1 million in Bitcoin and other cryptocurrencies** to diversify its treasury holdings. The company, following board approval, also enables future financings and transactions in cryptocurrency as part of its strategic financial strategy. This move aligns with broader industry trends toward digital asset integration in corporate treasury management.
Quantum Biopharma closes its first tranche of a funding offering, issuing 500 debenture units for **$500,000**. The company had previously announced the offering on December 5, 2024. This marks progress in securing capital through structured debt instruments.
Quantum Biopharma’s safety review committee advises beginning dosing for the second cohort in its Phase 1 multiple ascending dose trial of **Lucid-21-302 (Lucid-MS)**, a potential treatment for multiple sclerosis. The trial, conducted via subsidiary **HUGE Biopharma Australia**, follows a randomized, double-blind, placebo-controlled design. The company specializes in developing innovative biopharmaceutical assets.
Quantum BioPharma (formerly FSD Pharma) invites shareholders to participate in a **$700M+ lawsuit** filed against **CIBC World Markets, RBC Dominion Securities, and others** for alleged **spoofing and stock price manipulation**. The company claims the defendants artificially influenced its share price in U.S. courts. Quantum BioPharma operates under ticker symbols **QNTM** on NASDAQ, CSE, and FRA exchanges, following a rebrand from FSD Pharma (previously traded as **HUGE**).